Istanbul, Denizli and Izmir, Türkiye, 03 August 2025 – MicroPort® CardioFlow recently announced the first commercial implantations of its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Türkiye.
Five procedures were performed at Kocaeli University Hospital and Pamukkale University Hospital, led by Prof. Dr. Teoman Kilic, Director of Structural Heart Interventions at Kocaeli University and President of Turkish Working Group of Interventional Cardiology, in collaboration with Prof. Jianan Wang, Academician of the Chinese Academy of Sciences, and Prof. Xianbao Liu, Vice President of Zhejiang University School of Medicine.
All cases were successfully completed, with postoperative assessments confirmed device performance. Physicians highlighted the system’s precision, retrievability, and single-operator design, which streamlined workflow and improved efficiency.
VitaFlow Liberty® builds on the original VitaFlow® design, featuring a hybrid-density self-expanding stent, bovine pericardial leaflets, and a dual-layer PET skirt to enhance radial strength, coaxial deployment, and sealing. Its next-generation delivery system introduces a double-helix structure that ensures accurate deployment, retrievability, and 360-degree articulation at the valve segment.
These first-in-country cases demonstrate MicroPort® CardioFlow’s commitment to delivering advanced transcatheter valve technologies with the support of world-class clinical guidance, ensuring optimal outcomes for both physicians and patients.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation, HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic research and development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/